Citations

Showing 10 of 108094 citations.

Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
Treviño‐Rangel, Rogelio de J. , Montoya, Alexandra M. , Rojas, Olga C. , Elizondo-Zertuche, Mariana , Álvarez‐Villalobos, Neri Alejandro , Montoya, Alexandra M , Rojas, Olga C , Álvarez-Villalobos, Neri A , González, Gloria María

Mayo Clinic

Journal of Fungi | October 30, 2022 | Volume: 8 | Issue: 11 | Pages: 1144

10.3390/jof8111144 | PMID 36354911 Get It

The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals. These promising agents are currently in different stages of development, offering novel dosing regimens and mechanisms of action. A systematic search in MEDLINE, EMBASE, Web of Science, and Scopus up to 27 June 2022 was conducted to find relevant articles reporting data of in vitro activity and in vivo efficacy of investigational antifungals against C. auris. These included new additions to existing antifungal classes (rezafungin and opelconazole), first-in-class drugs such as ibrexafungerp, manogepix/fosmanogepix, olorofim and tetrazoles (quilseconazole, oteseconazole and VT-1598), as well as other innovative agents like ATI-2307, MGCD290 and VL-2397. From 592 articles retrieved in the primary search, 27 met the eligibility criteria. The most studied agent was manogepix/fosmanogepix (overall MIC90: 0.03 mg/L), followed by ibrexafungerp (overall MIC90: 1 mg/L) and rezafungin (overall MIC mode: 0.25 mg/L), while VT-1598 and ATI-2307 were the least explored drugs against C. auris. All these compounds demonstrated significant improvements in survival and reduction in tissue fungal burden on neutropenic animal models of candidemia due to C. auris. Continual efforts towards the discovery of new treatments against this multidrug-resistant fungus are essential.
Rationalizing rules for immunotherapy combination trials: About time for precision immunotherapy
Desai, Aakash , Subbiah, Vivek , Desai, Aakash P , Subbiah, Vivek

Mayo Clinic

Cancer | October 30, 2022 | Volume: 129 | Issue: 1 | Pages: 11-14

10.1002/cncr.34514 | PMID 36309827 Get It

Lay summaryImmunotherapy has changed the landscape of cancer treatment. However, the benefit of immunotherapy is seen only in some cases, with most patients experiencing cancer progression despite treatment with immunotherapy. To overcome this, combination immunotherapy treatments are being studied. Herein, we propose for a precision‐driven approach for patient selection to identify successful combinations of immunotherapy to improve outcomes for patients with cancer.
The Many Faces of NELL1 MN
Sethi, Sanjeev

Mayo Clinic

Clinical Kidney Journal | October 29, 2022 | Volume: 16 | Issue: 3 | Pages: 442-446

10.1093/ckj/sfac237 | PMID 36865014 Get It

ABSTRACT Neural tissue encoding protein with EGF-like repeats (NELL1) is a recently discovered target antigen in membranous nephropathy (MN). The initial study showed that most cases of NELL1 MN had no underlying disease associations, i.e. most cases of NELL1 MN were classified as primary MN. Subsequently, NELL1 MN has been found in the setting of various diseases. These include NELL1 MN associated with malignancy, drugs, infections, autoimmune disease, hematopoietic stem cell transplant, de novo MN in a kidney transplant and sarcoidosis. Thus there is marked heterogeneity in the diseases associated with NELL1 MN. Evaluation of an underlying disease associated with MN will likely need to be more exhaustive in NELL1 MN.
Reading Epilepsy and Language Processing: A Proposed Role for Semantic Salience
Li, Wentao , Seyal, Masud

Mayo Clinic

Journal of Clinical Neurophysiology | October 29, 2022 | Volume: 40 | Issue: 1 | Pages: e1-e5

10.1097/wnp.0000000000000955 | PMID 36308758 Get It

Summary: Reading epilepsy is a relatively rare reflex epilepsy syndrome that typically presents as orofacial reflex myoclonus triggered by reading. Seizures are thought to be because of activation of hyperexcitable language-related pathways in the dominant hemisphere that subsequently spreads to adjacent motor cortices. More difficult reading tasks are thought to be more provocative of seizures regardless of semantic understanding of the text. The authors sought to better characterize the role of text difficulty and comprehension in triggering seizures in a 27-year-old patient with reading epilepsy. As a part of his epilepsy monitoring unit admission, the patient underwent a series of reading trials with increasing semantic salience and/or difficulty, including pseudo-reading of colors and foreign-language texts, which demonstrated a positive correlation between spike count and clinical events and increasing semantic salience. This suggests that our novel reading task may be able to differentiate between different processes in the reading pathway and that increased semantic relevance of the text, rather than increased difficulty per se, can be associated with increased seizures in reading epilepsy. The authors theorize that this may be associated with his atypical (nondominant) right hemispheric seizure focus and propose that further study of patients with reading epilepsy syndrome may help elucidate the neurobiological networks involved in reading and language processing.
Ceramide Risk Scores Can Bring Lipidomics to Clinical Medicine
Ramos, Paola , Meeusen, Jeffrey W.

Mayo Clinic

Clinical Chemistry | October 29, 2022 | Volume: 68 | Issue: 12 | Pages: 1479-1480

10.1093/clinchem/hvac169 | PMID 36308336 Get It

Molecular and Immunophenotypic Correlates of Metastatic Epithelioid Angiomyolipoma Include Alterations of TP53 , RB1 , and ATRX
McCarthy, Michael R., Nichols, Paige , Sharma, Vidit , Stanton, Melissa, Halling, Kevin C. , Lohse, Christine M. , Herrera-Hernandez, Loren , Thompson, R. Houston, Leibovich, Bradley C. , Jiménez, Rafael E. , Boorjian, Stephen A. , Cheville, John C. , Gupta, Sounak , Nichols, Paige E, Stanton, Melissa L, Reynolds, Jordan , Pitel, Beth A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | October 29, 2022 | Volume: 147 | Issue: 7 | Pages: 817-825

10.5858/arpa.2022-0127-oa | PMID 36308711 Get It

Context.— Epithelioid angiomyolipomas (eAMLs) are rare tumors of the kidney that occur in patients with tuberous sclerosis complex or in a sporadic setting; a subset of these tumors exhibit metastatic behavior. Objective.— To analyze molecular profiling data to identify pathogenic alterations in rare cases of metastatic eAML, and to identify immunohistochemistry (IHC)-based surrogate markers. Design.— Molecular profiling data from the American Association for Cancer Research GENIE registry was accessed for 23 patients with angiomyolipomas, and 9 of 16 patients with eAMLs in our institutional registry were evaluated with next-generation sequencing. IHC was performed to screen for alterations of P53, RB, and ATRX for all 16 institutional cases. Results.— Combined alterations of 5 tumor-suppressor genes (TP53, ATRX, RB1, APC, and NF1) were identified using next-generation sequencing in 7 of 8 (88%) patients with metastatic disease compared to a single patient with nonmetastatic disease (RB1 variant of uncertain significance; 1 of 24, 4%). No cases with abnormal IHC results were identified in 11 patients with nonmetastatic disease compared to 3 of 5 patients with metastatic disease. Conclusions.— Our results show that the majority of metastatic eAMLs have mutations of 5 tumor-suppressor genes (TP53, ATRX, RB1, APC, and NF1), while these are rare in patients with nonmetastatic disease. Furthermore, IHC for P53, RB, and ATRX may serve as a screen for a subset of these alterations in resource-limited settings. These findings, if validated in larger data sets, have the potential to predict metastatic behavior in eAMLs.
Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice
Moura, Marta Casal , Fervenza, Fernando C. , Warrington, Kenneth J. , Berti, Alvise , Casal Moura, Marta , Fervenza, Fernando C , Warrington, Kenneth J , Berti, Alvise , Chevet, Baptiste , Cornec, Divi , Gall, Émilie Cornec-Le , Specks, Ulrich

Mayo Clinic

Rheumatology | October 29, 2022 | Volume: 62 | Issue: 5 | Pages: 1787-1803

10.1093/rheumatology/keac623 | PMID 36315063 Get It

Abstract ANCA-associated vasculitides (AAV) are a group of rare, primary, systemic necrotizing small-vessel vasculitides. Granulomatosis with polyangiitis and microscopic polyangiitis account for ∼80–90% of all AAV. Exposure to silica dust, farming and chronic nasal Staphylococcus aureus carriage are associated with increased risk of developing AAV. When a diagnosis of AAV is suspected, as in patients with multisystem organ dysfunction or those with features such as chronic recurrent rhinosinusitis, cavitated lung nodules, palpable purpura or acute kidney injury, then appropriate further investigations are needed, including ANCA testing. In this scenario, a structured clinical assessment should be conducted, evaluating all the organs possibly involved, and tissue biopsy may be necessary for confirmation of the diagnosis. Therapeutic algorithms vary based on the severity of AAV, the clinical diagnosis/ANCA specificity, and the patient’s age, weight, comorbidities and prognosis. Recent data favour rituximab as a preferable option for both induction and maintenance of remission. In addition, regimens with less glucocorticoids are equally effective and safer in inducing remission compared with conventional regimens, and avacopan is an effective glucocorticoid-sparing option. In contrast, there is not compelling evidence to support the routine use of plasma exchange in addition to standard remission-induction therapy in AAV. ANCA and other biomarkers can be helpful in association with clinical assessment to guide diagnosis and treatment decisions. Patients should be frequently evaluated during follow-up for possible disease relapses or treatment-related morbidity, and for monitoring damage accrual, especially metabolic and cardiovascular damage.
Measuring brain beats: Cardiac‐aligned fast functional magnetic resonance imaging signals
Hermes, Dora , Wu, Hua , Kerr, Adam B. , Wandell, Brian A. , Hermes, Dora

Mayo Clinic

Human Brain Mapping | October 29, 2022 | Volume: 44 | Issue: 1 | Pages: 280-294

10.1002/hbm.26128 | PMID 36308417 Get It

Abstract Blood and cerebrospinal fluid (CSF) pulse and flow throughout the brain, driven by the cardiac cycle. These fluid dynamics, which are essential to healthy brain function, are characterized by several noninvasive magnetic resonance imaging (MRI) methods. Recent developments in fast MRI, specifically simultaneous multislice acquisition methods, provide a new opportunity to rapidly and broadly assess cardiac‐driven flow, including CSF spaces, surface vessels and parenchymal vessels. We use these techniques to assess blood and CSF flow dynamics in brief (3.5 min) scans on a conventional 3 T MRI scanner in five subjects. Cardiac pulses are measured with a photoplethysmography (PPG) on the index finger, along with functional MRI (fMRI) signals in the brain. We, retrospectively, align the fMRI signals to the heartbeat. Highly reliable cardiac‐gated fMRI temporal signals are observed in CSF and blood on the timescale of one heartbeat (test–retest reliability within subjects R 2 > 50%). In blood vessels, a local minimum is observed following systole. In CSF spaces, the ventricles and subarachnoid spaces have a local maximum following systole instead. Slower resting‐state scans with slice timing, retrospectively, aligned to the cardiac pulse, reveal similar cardiac‐gated responses. The cardiac‐gated measurements estimate the amplitude and phase of fMRI pulsations in the CSF relative to those in the arteries, an estimate of the local intracranial impedance. Cardiac aligned fMRI signals can provide new insights about fluid dynamics or diagnostics for diseases where these dynamics are important.
Dexmedetomidine‐associated diabetes insipidus during skull base surgery in a pediatric patient
Reynolds, Emily G. , Decar, Lauren M. Van, Sharpe, Emily E. , Harbell, Monica W. , Van Decar, Lauren M, Kraus, Molly B , Harbell, Monica W , Sharpe, Emily E , Decar, Lauren Van, Kraus, Molly B.

Mayo Clinic

Pediatric Anesthesia | October 29, 2022 | Volume: 33 | Issue: 3 | Pages: 250-253

10.1111/pan.14587 | PMID 36308013 Get It

AbstractDiabetes insipidus is characterized by polyuria due to an inability to auto‐regulate water balance resulting in dangerous metabolic derangements. Intraoperative anesthetics have been increasingly identified as a cause of diabetes insipidus in adult patients; however, it is rare in pediatrics. We present a case of a 16‐year‐old male undergoing resection of a recurrent left juvenile nasopharyngeal angiofibroma who experienced intraoperative polyuria concerning diabetes insipidus. Urine output drastically decreased following discontinuation of dexmedetomidine with complete resolution within 24 h. We conclude that this case of transient diabetes insipidus was associated with dexmedetomidine administration.
Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials
DuRoss, Allison N., Guimarães, Alexander R. , Baas, Carole , Krishnan, Sunil , Thomas, Charles R., Sun, Conroy , Bagley, Alexander F. , Krishnan, Sunil , Sun, Conroy , Bagley, Alexander F , Phan, Jack , Lazar, Alexander J. , Walker, Joshua M.

Mayo Clinic

WIREs Nanomedicine and Nanobiotechnology | October 29, 2022 | Volume: 15 | Issue: 3 | Pages: No page available

10.1002/wnan.1867 | PMID 36308008 Get It

AbstractRadioenhancing nanoparticles (NPs) are being evaluated in ongoing clinical trials for various cancers including head and neck, lung, esophagus, pancreas, prostate, and soft tissue sarcoma. Supported by decades of preclinical investigation and recent randomized trial data establishing clinical activity, these agents are poised to influence future multimodality treatment paradigms involving radiotherapy. Although the physical interactions between NPs and ionizing radiation are well characterized, less is known about how these agents modify the tumor microenvironment, particularly regarding tumor immunogenicity. In this review, we describe the key multidisciplinary considerations related to radiation, surgery, immunology, and pathology for designing radioenhancing NP clinical trials.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease